Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia

Compact, single-use, and simple-to-use technology offers orthopedic surgeons a fast, reliable navigation solution for hip arthroplasty 

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons - and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments. This exclusive distribution builds upon the agreement Smith+Nephew announced for Japan in April 2023.

From left: Ms Ameneh Sadeghpour (COO, Navbit), Mr Mayank Shandil (SVP, Global Orthopedics Marketing, S+N), Prof. Bill Walter (Founder, Navbit), Mr Kenneth Garcia (SVP & GM, International Markets Orthopedics, S+N), Ms Lynette Walter (CEO, Navbit), Mr Damon Mogridge (Sr. BU Director, ANZ Orthopedics, S+N)

Lynette Walter, NAVBIT’s CEO said, “We are absolutely delighted to expand our partnership with Smith+Nephew into the Australian market. We are committed to supporting and serving our great Australian surgeons with smart, useful technologies - and we look forward to complementing the Smith+Nephew implant range with this very neat navigation technology.”

“We are seeing the positive impact that NAVBIT SPRINT™ offers our customers in Japan and look to experience the same results in the Australian market” noted Kenneth Garcia, Senior Vice President and General Manager, International Orthopedics for Smith+Nephew. “Many customers are seeking innovative solutions for planning and execution of hip arthroplasty and NAVBIT will help us serve that specific market segment.”

Post-operative dislocation remains the second most common reason for revision of a total hip replacement in registries around the world^1-4 as data suggests only 49% of acetabular cups are accurately aligned when using manual instrumentation⁶. Simran Sabharwal, Vice President Global Hip Marketing for Smith+Nephew explained that, “NAVBIT SPRINT offers an innovative enabling technology solution that has been proven to address inaccuracies in cup placement, thereby reducing the risk of dislocation while providing efficiencies in the episode of care.”

“In the past, surgery was more art than science. Today we have higher expectations around the accuracy and precision of our surgery,” said Professor Bill Walter, Orthopaedic Surgeon and Founder of NAVBIT. “Outliers are becoming less acceptable to surgeons and to patients. Surgeons will have to answer the question: If there is a technology available that can make you more accurate, why are you not using it?"

NAVBIT SPRINT™ is available through Smith+Nephew in Japan and Australia and has two product variants: for supine patient position and for lateral patient position; making is suitable for a range of surgical approaches, including the direct anterior approach and the posterior approach.

Enquiries

About Smith+Nephew

Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F,  which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.